Premium
Onset of action of mometasone furoate nasal spray (NASONEX ® ) in seasonal allergic rhinitis [Note 2. The copyright in this article does not belong to ...]
Author(s) -
Berkowitz Rb,
Bernstein Di,
LaForce C,
Pedinoff Aj,
Rooklin Ar,
Damaraju Crv,
Mesarinawicki B,
Nolop Kb
Publication year - 1999
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1034/j.1398-9995.1999.00713.x
Subject(s) - mometasone furoate , medicine , placebo , nasal spray , adverse effect , allergy , onset of action , corticosteroid , nasal administration , immunology , alternative medicine , pathology
Background :Mometasone furoate nasal spray (MFNS, NASONEX ® ), is a new synthetic corticosteroid with considerable efficacy in the treatment of seasonal and perennial rhinitis and less than 0.1% systemic absorption. This study was designed to evaluate the time of onset of action of MFNS. The subjects were evaluated over the course of 2 weeks during the spring allergy season. Methods :The effects of MFNS 200 μg given once daily for 2 weeks were evaluated in a randomized, multicenter, double‐blind, placebo‐controlled study in 201 patients with seasonal allergic rhinitis. Clinically significant onset of action was assessed prospectively by special patient diary cards kept during the first 3 days of treatment. Results :By 12 h after initial dosage (the earliest evaluation), 28% of patients in the MFNS group experienced clinically significant relief, compared with 13% of those given placebo ( P =0.01). Median time to at least moderate symptom relief in patients who received MFNS was 35.9 h, compared with more than 72 h in patients given placebo ( P <0.01). By 72 h, 64% of the patients receiving MFNS experienced at least moderate relief, compared with 40% of those treated with placebo ( P <0.01). Both patient and physician ratings of symptom severity, response to treatment, and overall condition of rhinitis indicated significant ( P <0.01) superiority of MFNS over placebo. MFNS was well tolerated, with adverse events comparable to placebo. Conclusions :MFNS provided rapid onset of clinically significant symptom relief in patients with seasonal allergic rhinitis.